IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Sabanayagam et al.

Application No.: To be assigned

Group No.: 1655

Filed: Herewith

Examiner: Lu, F.

For: NUCLEIC ACID ARRAYS AND METHODS OF SYNTHESIS

Box Sequence Assistant Commissioner for Patents Washington, D.C. 20231

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

Applicants are submitting simultaneously herewith a new continuation application. This sequence listing is being submitted herewith.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Ronald I. Eisenstein, state the following:

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

x deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

with sufficient postage as first class mail.

Date: 6/21/01

X

as "Express Mail Post Office to Address"

Mailing Label No. EL565099250US (mandatory)

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Patricia W. Turner

(type or print name of person certifying)

(Submission-Nucleotide and/or Amino Acid Sequence,page 1 of 3)

etricia W. Iarner

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.

A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

Because this submission is made in fulfilling the requirement under 37 C.F.R. § 1.821(g), a statement that the submission includes no new matter.

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

The "Sequence Listing" and computer readable copy are the same.

STATUS

5. Applicant is a small entity; a small entity statement was filed October 12, 1999.

EXTENSION OF TERM

6. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

If any additional extension and/or fee is required, charge Account No. 50-0850.

SIGNATURE OF PRACTITIONER

Reg. No. 30,628 Tel. No.: (617) 345-6054

Customer No. 26248

Ronald I. Eisenstein NIXON PEABODY LLP 101 Federal Street Boston, MA 02110

SEQUENCE LISTING

```
<110> Sabanayagam, Chandran R.
                                                     Sano, Takeshi
                                                    Misasi, John
                                                    Hatch, Anson
                                                     Cantor, Charles
                        <120> Nucleic Acid Arrays and Methods of Synthesis
                        <130> 50113: Sabanayagam et al.
                        <140> 09/287,781
                        <141> 1999-04-08
                        <150> 60/081,254
                        <151> 1998-04-09
                        <160> 11
                        <170> PatentIn Ver. 2.1
                        <210> 1
 Harm them says the first factor of the first f
                       <211> 15
                        <212> DNA
                        <213> Artificial Sequence
                        <220>
                        <223> Description of Artificial Sequence:recombinant
 $1 00 mm bed
                        <400> 1
                                                                                                                                                                                                                                                                                                                                                15
                        attatgctat tttgg
<210> 2
                        <211> 6
                        <212> DNA
                        <213> Artificial Sequence
                        <220>
                        <223> Description of Artificial Sequence:recombinant
                        <400> 2
                                                                                                                                                                                                                                                                                                                                                 6
                        aaaacc
                        <210> 3
                        <211> 11
```

	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: recombinant	
	<400> 3	
	acgataaaac c	11
	<210> 4	
	<211> 74	
	<212> DNA	
	<213> Artificíal Sequence	
	<220>	
	<223> Description of Artificial Sequence: recombinant	
	<400> 4	
	ctgtcatcat ttgtgaacta atacaccaat aactaataca ccaataacta atacaccaac	60
	gcttggctat ccat	74
or the free		
	<210> 5	
	<211> 53	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: recombinant	
	<400> 5	
	cctaaactca cggcgatgaa cgccacaaat gatgacagat ggatagccaa gcg	53
A STATE OF THE STA	<210> 6	
77777	<211> 53	
world may be to be a form the part of the	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence:recombinant	
	<400> 6	
	cctaaactca cggcgatgaa cgccacaaat gatgacatat ggatagccaa gcg	53
	<210> 7	

<211> 74	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: recombinant	
<400> 7	
tgtcatcatt tgtgaactaa tacaccaata actaatacac caataactaa tacaccaacg	60 74
cttggctate cate	74
<210> 8	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:recombinant	
<400> 8	
catcgccgtg agtttagg	18
<223> Description of Artificial Sequence: recombinant	
<400> 9	1 4
aactaataca ccaa	14
<010> 10	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence:recombinant	
<400> 10	
caatttcaca caggcccaag	20
	<pre><212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:recombinant <400> 7 tgtcatcatt tgtgaactaa tacaccaata actaatacac caataactaa tacaccaacg cttggctatc catc <210> 8 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:recombinant <400> 8 catcgccgtg agtttagg <210> 9 <211> 14 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:recombinant <400> 9 actagccgtg agtttagg <210> 9 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:recombinant <400> 9 aactaataca ccaa <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence:recombinant <400> 10</pre>

```
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:recombinant
<400> 11
cgtaagactc atgctcaagc
```